Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

232
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
232
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

140
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
140
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.0K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.0K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

374
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
374

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Birth prevalence and characterisation of congenital hyperinsulinism in Western Australia over two decades.

Journal of pediatric endocrinology & metabolism : JPEM·2026
Same author

Impact of the 2025 Endocrine Society clinical practice guideline on the diagnosis and management of primary aldosteronism for the clinical laboratory.

Pathology·2026
Same author

Injectable, oral, gene-based, and vaccine-driven PCSK9-targeted therapies: emerging clinical insights shaping the future of hypercholesterolemia management.

Expert opinion on emerging drugs·2026
Same author

<i>ANGPTL3</i> gene editing with CRISPR-Cas9: early trial insights.

Expert opinion on investigational drugs·2026
Same author

Assessing the clinical development of zerlasiran, a small-interfering RNA for elevated lipoprotein(a).

Expert opinion on investigational drugs·2025
Same author

Enhancing the detection of familial hypercholesterolaemia in general practice: A model for supporting genetic cascade testing in the community.

European journal of human genetics : EJHG·2025
Same journal

Editorial introduction.

Current opinion in lipidology·2026
Same journal

Heterozygosity for pathogenic variants in familial chylomicronemia syndrome genes: from carrier state to complex trait.

Current opinion in lipidology·2026
Same journal

Premature atherosclerotic cardiovascular disease in the MENA region: economic impact, barriers to care, and policy recommendations for an escalating crisis.

Current opinion in lipidology·2026
Same journal

The role of metabolic profiling and dietary intervention in the early diagnosis and prevention of atherosclerosis.

Current opinion in lipidology·2026
Same journal

A JAK of two trades: beneficial or adverse effects of Janus kinase inhibition for plasma LDL-cholesterol and major adverse cardiovascular events in inflammatory bowel disease patients?

Current opinion in lipidology·2026
Same journal

Inflammation and atherosclerotic cardiovascular disease: where do we go from here?

Current opinion in lipidology·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.7K

Tangier disease: update for 2020.

Amanda J Hooper1,2, Robert A Hegele3, John R Burnett1,2

  • 1Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital & Fiona Stanley Hospital Network.

Current Opinion in Lipidology
|February 6, 2020
PubMed
Summary
This summary is machine-generated.

Recent advances in Tangier disease reveal increased atherosclerotic cardiovascular disease (ASCVD) risk in carriers of ABCA1 variants. New insights also focus on neurological issues and potential therapies for this rare genetic HDL deficiency disorder.

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Related Experiment Videos

Last Updated: Dec 29, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.7K
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.7K

Area of Science:

  • Lipid metabolism and genetic disorders
  • Cardiovascular disease research
  • Neurology and rare diseases

Background:

  • Tangier disease is a rare genetic disorder characterized by severe HDL deficiency.
  • It is associated with premature atherosclerotic cardiovascular disease (ASCVD) and neurological abnormalities.
  • Limited literature exists on its full spectrum of clinical manifestations.

Purpose of the Study:

  • To review recent advancements in understanding Tangier disease.
  • To explore new evidence regarding ASCVD risk in ABCA1 variant carriers.
  • To summarize progress in assessing and treating neurological complications.

Main Methods:

  • Literature review of recent studies on Tangier disease.
  • Analysis of new evidence on ABCA1 variants and ASCVD risk.
  • Examination of research on neurological manifestations and therapies.

Main Results:

  • New evidence indicates increased ASCVD risk for heterozygous ABCA1 variant carriers.
  • Advances have been made in assessing neurological abnormalities in Tangier disease.
  • Potential new therapies for neurological deficits are being identified.

Conclusions:

  • Tangier disease presents significant risks including premature ASCVD and neuropathy.
  • ABCA1 variant carriers may also face elevated ASCVD risk.
  • Further research and patient registries are needed to fully understand this rare condition.